复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗的1期临床试验申请获美国食品药品管理局批准

19 12 月, 2025

One Min Read

9 Views

Last Update: 19 12 月, 2025

Written By

Other Articles

Previous

The new American Dream has parents easing up on college expectations for their kids: 35% are now open to trade school instead

Next

绿城服务(02869)12月19日斥资191.4万港元回购42.2万股

Related Posts

先消灭低价股！

1 Min Read

假期市场思考：A股还是美股？

1 Min Read

香港证券两日成交额破百亿！港股仍有市场？

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept